Trump’s Pharma Tariff Spares Generics, but India Still Feels Heat

Lalit K Jha

Washington, Sept. 26 (5WH):

President Donald Trump announced on Thursday a 100% tariff on branded and patented pharmaceutical imports, effective October 1, 2025, unless companies establish manufacturing facilities in the United States. While generic medicines — India’s main export to America — are excluded on paper, the move has the potential to unsettle the $20 billion industry that supplies nearly 40 per cent of US generics.

He said “IS BUILDING” would mean “breaking ground” or “under construction,” adding that products from firms already investing in U.S. facilities would not face tariffs.

The announcement has sent ripples through the global pharmaceutical industry. By explicitly targeting branded and patented medicines, the measure spares generics — the lower-cost versions produced once patents expire.

For India, the world’s largest supplier of generics to the United States, that distinction provides only partial relief. Indian companies ship about $20 billion worth of generics to America each year, with Sun Pharma, Dr Reddy’s Laboratories, Cipla, Lupin, and Aurobindo Pharma among the major exporters.

Industry analysts say the absence of generics in Trump’s order does not eliminate the risk for India. Many firms also manufacture ingredients and formulations for branded products through contract arrangements with multinational companies.

Those partnerships could be disrupted if the finished drugs are subject to taxation. Others worry about how U.S. authorities will interpret the term “branded.” Even generics carry a manufacturer’s label, and a broad or inconsistent definition could mean Indian shipments face delays, scrutiny, or additional costs at customs.

The larger concern is the direction of U.S. policy. Trump’s carve-out for companies “building” plants in America is widely seen as a signal to drugmakers that they must establish manufacturing capacity on U.S. soil. For India’s biggest exporters, investing in American facilities would mean higher capital costs and thinner margins. For smaller firms, meeting the demand may be impossible.

The tariff also threatens to distort the U.S. pharmaceutical market. If branded drugs become more expensive due to import duties, demand for generic alternatives could increase in the short term, which might benefit Indian suppliers. But a sudden surge in reliance on imported generics could just as easily prompt Washington to clamp down further and push aggressively for domestic production of lower-cost medicines.

“This is less about the immediate blow and more about the future trajectory of U.S. trade policy,” said one Indian American pharma analyst.

For U.S. patients, the implications of the pharmaceutical tariff are significant. Generics have long been the linchpin in keeping drug prices affordable, with Indian companies supplying treatments for everything from cancer to infectious diseases. Even the hint of disruption could lead to higher costs or shortages in critical categories. Health policy experts warn that while the push to reshore manufacturing may serve long-term strategic goals, it risks undermining supply stability in the short term.

Trump’s pharmaceutical announcement was part of a broader protectionist push on Thursday.

He also said his administration would impose a 50 per cent tariff on kitchen cabinets, bathroom vanities, and associated products, citing what he called “large-scale ‘FLOODING’” of imports. A 30 per cent tariff will apply to upholstered furniture, while imported heavy trucks will face a 25 per cent levy. Trump named Peterbilt, Kenworth, Freightliner and Mack Trucks as U.S. manufacturers that would benefit, saying the measure was necessary “for National Security purposes.”

This story is originally from 5WH.

(5WH/VK)